Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective

The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective

ByMichael Heile, MD, FAAFP,Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP

December 15th 2020

Type 2 Diabetes in the US Managed Care Setting: The Burden of Disease and Rationale for an Oral Glucagon-like Peptide-1 Receptor Agonist

ByTanya Dougherty, PharmD, BCPS,Michael Heile, MD, FAAFP

December 14th 2020

Efficacy of Oral Semaglutide: Overview of the PIONEER Clinical Trial Program and Implications for Managed Care

ByHelena W. Rodbard, MD, FACP, MACE,Tanya Dougherty, PharmD, BCPS,Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP

December 13th 2020

Cardiovascular Outcomes, Safety, and Tolerability With Oral Semaglutide: Insights for Managed Care

ByIldiko Lingvay, MD, MPH, MSCS,Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP,Tanya Dougherty, PharmD, BCPS

December 12th 2020

The Importance of Patient-Reported Outcomes in Type 2 Diabetes: Insight From the PIONEER Program With Oral Semaglutide

ByDoron Schneider, MD,Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP,Tanya Dougherty, PharmD, BCPS

December 11th 2020

Full Video Abstract: Evidence for Oral Semaglutide in Type 2 Diabetes

December 10th 2020

Participating Faculty for the Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective

December 9th 2020

Trending on AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes

Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD